NASDAQ:PHXM PHAXIAM Therapeutics (PHXM) Stock Price, News & Analysis → [Urgent!] Generational Wealth Gameplan (From Crypto 101 Media) (Ad) Free PHXM Stock Alerts $3.10 0.00 (0.00%) (As of 06/4/2024 ET) Add Compare Share Share Today's Range$3.10▼$3.1050-Day Range$3.10▼$3.1052-Week Range$2.50▼$13.00VolumeN/AAverage Volume2,472 shsMarket Capitalization$10.58 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends Get PHAXIAM Therapeutics alerts: Email Address Ad Weiss RatingsProtect Your Bank Account Before It’s Too LateFor months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …Stop right now and do these 3 things to protect yourself About PHAXIAM Therapeutics Stock (NASDAQ:PHXM)PHAXIAM Therapeutics S.A., a biopharmaceutical company, focuses on developing treatments for resistant bacterial infections in France and the United States. It develops eryaspase, which is in Phase 3 clinical development for the treatment of second-line pancreatic cancer, and in Phase 2 stage for the treatment of triple-negative breast cancer and second-line acute lymphoblastic leukemia patients. The company also engages in developing a portfolio of phages targeting resistant and dangerous bacteria, which together account for more than two-thirds of resistant hospital-acquired infections, including staphylococcus aureus, escherichia coli, and pseudomonas aeruginosa. The company was formerly known as ERYTECH Pharma S.A. and changed its name to PHAXIAM Therapeutics S.A. in June 2023. PHAXIAM Therapeutics S.A. was incorporated in 2004 and is headquartered in Lyon, France.Read More PHXM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PHXM Stock News HeadlinesMay 15, 2024 | finanznachrichten.dePhaxiam Therapeutics S.A.: PHAXIAM provides Business and Financial Update for the First Quarter of 2024May 15, 2024 | globenewswire.comPHAXIAM provides Business and Financial Update for the First Quarter of 2024April 15, 2024 | msn.comPhaxiam enrols first patient in endocarditis infection studyApril 15, 2024 | globenewswire.comPHAXIAM Therapeutics announces enrolment of the first patient in the phase 1 study for the treatment of endocarditis infections caused by Staphylococcus aureusApril 5, 2024 | finanznachrichten.dePhaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)April 5, 2024 | globenewswire.comPHAXIAM Therapeutics announces filing of its 2023 Universal Registration Document (URD)March 23, 2024 | seekingalpha.comONCT Oncternal Therapeutics, Inc.March 20, 2024 | globenewswire.comPHAXIAM Announces 2023 Full-Year Results and Provides Business UpdateMarch 11, 2024 | finanznachrichten.dePhaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock MarketMarch 11, 2024 | markets.businessinsider.comPhaxiam Therapeutics Says Delisting Of ADSs From Nasdaq EffectiveMarch 11, 2024 | globenewswire.comPHAXIAM Therapeutics announces effectiveness of voluntary delisting of American Depositary Shares from Nasdaq Stock MarketMarch 5, 2024 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital - February 29, 2024February 20, 2024 | globenewswire.comPHAXIAM Therapeutics announces intention to voluntary delist American Depositary Shares from The Nasdaq Capital MarketFebruary 7, 2024 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital - January 31, 2024January 19, 2024 | finanznachrichten.dePhaxiam Therapeutics S.A.: PHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024January 18, 2024 | finance.yahoo.comPHAXIAM Therapeutics announces its cash position at the end of 2023 and its financial calendar for 2024January 3, 2024 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital - December 31, 2023December 6, 2023 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital - November 30, 2023November 28, 2023 | lse.co.ukPhaxiam Therapeutics Share Price (PHXM.PA)November 15, 2023 | finanznachrichten.dePhaxiam Therapeutics S.A.: PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023November 14, 2023 | morningstar.comPHAXIAM Therapeutics SA ADR PHXMNovember 14, 2023 | finance.yahoo.comPHAXIAM Provides Business and Financial Update for the Third Quarter of 2023November 11, 2023 | morningstar.comPHAXIAM Therapeutics SA ADRNovember 7, 2023 | finance.yahoo.comMonthly information related to total number of voting rights and shares composing the share capital _ October 31, 2023October 29, 2023 | investing.comPhaxiam Therapeutics SA DRC (PHXM)See More Headlines Receive PHXM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PHAXIAM Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today6/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:PHXM CUSIPN/A CIK1624422 Weberytech.com Phone33478744438Fax33-4-78-75-56-29Employees49Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.23 Current Ratio1.78 Quick RatioN/A Sales & Book Value Annual Sales$32.66 million Price / Sales0.32 Cash FlowN/A Price / Cash FlowN/A Book Value$7.98 per share Price / Book0.39Miscellaneous Outstanding Shares3,412,000Free Float3,346,000Market Cap$10.58 million OptionableNo Data Beta2.35 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Eric Soyer Ph.D. (Age 58)Deputy CEO, Deputy GM, CFO & COO Comp: $415.06kDr. Jérôme Bailly Pharm.D. (Age 45)Deputy CEO, Deputy GM, Chief Quality Officer & Qualified Person Comp: $270.98kMr. Thibaut du Fayet (Age 56)Chief Executive Officer Ms. Céline Breda (Age 53)Chief Technology Officer Ms. Cindy FevreChief Scientific OfficerNaomi EichenbaumDirector Investor RelationsMs. Anne-Cécile Fumey (Age 48)Vice President of Human Resources Ms. Karine Charton Ph.D.Chief Business OfficerDr. Pascal Birman M.D.Chief Medical OfficerMs. Frederique VievilleChief Regulatory OfficerMore ExecutivesKey CompetitorsLianBioNASDAQ:LIANKaleido BiosciencesNASDAQ:KLDO9 Meters BiopharmaNASDAQ:NMTRPolarityTENASDAQ:PTEIQHumanigenNASDAQ:HGENView All Competitors PHXM Stock Analysis - Frequently Asked Questions How have PHXM shares performed in 2024? PHAXIAM Therapeutics' stock was trading at $4.44 at the start of the year. Since then, PHXM shares have decreased by 30.2% and is now trading at $3.10. View the best growth stocks for 2024 here. When did PHAXIAM Therapeutics' stock split? PHAXIAM Therapeutics's stock reverse split on the morning of Wednesday, September 20th 2023. The 1-10 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. How do I buy shares of PHAXIAM Therapeutics? Shares of PHXM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PHXM) was last updated on 6/4/2024 by MarketBeat.com Staff From Our PartnersWas the Great Financial Crisis fun?The Great Financial Crisis, which actually started in the summer of 2007 and did not end until March of 2009, ...Brooks Enterprises| SponsoredCollapse of the Petrodollar The death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals| SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club| Sponsored[Webinar] Understanding Covered CallsDiscover the details of this option-selling strategy.OIC| SponsoredWhat’s Pelosi Buying Now?They Make the Top Investors Look Like Amateurs They beat the market for three years straight… avoided some ...Altimetry| SponsoredShocking $16T Elon Musk Crypto LeakReports of a leaked meeting between Elon Musk and staff at X.com could send shockwaves through the crypto mark...Crypto 101 Media| SponsoredElon Musk’s Final Masterpiece: “X-9840”The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Ju...Paradigm Press| SponsoredAre You Positioned For The New Energy Goldrush?Open AI’s Sam Altman recently helped this company raise $577 million in funding… What’s more is, It has alr...Wealthpin Pro| Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PHAXIAM Therapeutics S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share PHAXIAM Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.